The altered protein - IRAK-M - causes the immune system to become supercharged, clearing out the bacteria before they can do any damage.
"When we tested mice with the altered IRAK-M protein, they had less inflammation overall and remarkably less cancer," said Coy Allen, assistant professor at Virginia-Maryland College of Veterinary Medicine in the US.
The next step, he said, will be to evaluate these findings in human patients.
"Ultimately, if we can design therapeutics to target IRAK-M, we think it could be a viable strategy for preventing inflammatory bowel disease and cancer," said Allen.
The study was published in the journal eBioMedicine.